TrialCancer immunology, immunotherapy : CII2018

Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.

Mark R Albertini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.